



July 28, 2016

Dicerna to Report Second Quarter 2016 Financial Results and Host Conference Call on August 4, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2016 financial results after market close on Thursday, August 4, 2016.

Management will conduct a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and will be available on the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website.

The call can also be accessed by dialing (855) 453-3834 or (484) 756-4306 (international), and referencing conference ID 49039068 prior to the start of the call. After the conference call, a replay will be available until August 11, 2016. To access the replay, please dial (855) 859-2056 or (404) 537-3406, and refer to conference ID 49039068.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver, for other therapeutic areas in which the liver plays a key role, and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In many cases, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize these novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160728005205/en/>

Investors:

Rx Communications Group
Melody Carey, 917-322-2571
mcarey@rxir.com

or

Media:

SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media